Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2024 | $16.00 → $20.00 | Equal Weight → Overweight | Wells Fargo |
| 9/13/2024 | $17.00 → $20.00 | Neutral → Buy | Citigroup |
| 1/30/2024 | $21.00 | Buy | Deutsche Bank |
| 10/17/2023 | $16.00 | Outperform → Market Perform | BMO Capital Markets |
| 10/16/2023 | $13.00 → $15.00 | Underweight → Equal Weight | Wells Fargo |
| 10/10/2023 | $14.00 → $16.00 | Neutral → Buy | BofA Securities |
| 10/3/2023 | $16.00 | Outperform | Wedbush |
| 9/20/2023 | $11.00 → $15.00 | Hold → Buy | Jefferies |
Wells Fargo upgraded Sabra Health Care REIT from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously
Citigroup upgraded Sabra Health Care REIT from Neutral to Buy and set a new price target of $20.00 from $17.00 previously
Deutsche Bank initiated coverage of Sabra Health Care REIT with a rating of Buy and set a new price target of $21.00
4 - Sabra Health Care REIT, Inc. (0001492298) (Issuer)
4 - Sabra Health Care REIT, Inc. (0001492298) (Issuer)
4 - Sabra Health Care REIT, Inc. (0001492298) (Issuer)
SC 13G/A - Sabra Health Care REIT, Inc. (0001492298) (Subject)
SC 13G/A - Sabra Health Care REIT, Inc. (0001492298) (Subject)
SC 13G/A - Sabra Health Care REIT, Inc. (0001492298) (Subject)
Sabra Health Care REIT, Inc. ("Sabra," the "Company" or "we") (NASDAQ:SBRA) today announced its results of operations for the third quarter of 2024. THIRD QUARTER 2024 RESULTS AND RECENT EVENTS Results per diluted common share for the third quarter of 2024 were as follows: Net Income: $0.13 FFO: $0.34 Normalized FFO: $0.35 AFFO: $0.36 Normalized AFFO: $0.37 EBITDARM Coverage Summary: Skilled Nursing/Transitional Care: 1.94x Senior Housing - Leased: 1.37x Behavioral Health, Specialty Hospitals and Other: 3.68x Same store managed senior housing Cash NOI increased 17.8% on a year-over-year basis. As previously announced, in the third quarter of 2024, Sabra close
Sabra Health Care REIT, Inc. (NASDAQ:SBRA) announced today that it will issue its 2024 third quarter earnings release on October 31, 2024, after the close of trading. A conference call with a simultaneous webcast to discuss the 2024 third quarter results will be held on Friday, November 1 at 10:00 a.m. Pacific Time. The dial-in number for U.S. participants is 888-880-4448. For participants outside the U.S., the dial-in number is 646-960-0572. The conference ID number is 1382596. The webcast URL is https://events.q4inc.com/attendee/444925126. A digital replay of the call will be available on our website at www.sabrahealth.com. About Sabra Sabra Health Care REIT, Inc., a Maryland corporat
Sabra Health Care REIT, Inc. ("Sabra," the "Company" or "we") (NASDAQ:SBRA) today announced its results of operations for the second quarter of 2024. SECOND QUARTER 2024 RESULTS AND RECENT EVENTS Results per diluted common share for the second quarter of 2024 were as follows: Net Income: $0.10 FFO: $0.35 Normalized FFO: $0.35 AFFO: $0.36 Normalized AFFO: $0.36 EBITDARM Coverage Summary: Skilled Nursing/Transitional Care: 1.85x Senior Housing - Leased: 1.35x Behavioral Health, Specialty Hospitals and Other: 3.69x Same store managed senior housing Cash NOI increased 17.7% on a year-over-year basis. Investment activity through June 30, 2024 amounts
Sabra Health Care REIT, Inc. (NASDAQ:SBRA) announced today that Rick Matros, the company's Chair and Chief Executive Officer, Michael Costa, the company's Chief Financial Officer, Darrin Smith, the company's Executive Vice President of Investments, and Lukas Hartwich, the company's Senior Vice President of Finance, will attend Nareit's REITworld 2024 Annual Conference on November 19-20, 2024 at the Wynn Las Vegas in Las Vegas, Nevada. About Sabra Sabra Health Care REIT, Inc., a Maryland corporation, operates as a self-administered, self-managed real estate investment trust (a "REIT") that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout
Sabra Health Care REIT, Inc. ("Sabra," the "Company" or "we") (NASDAQ:SBRA) today announced its results of operations for the third quarter of 2024. THIRD QUARTER 2024 RESULTS AND RECENT EVENTS Results per diluted common share for the third quarter of 2024 were as follows: Net Income: $0.13 FFO: $0.34 Normalized FFO: $0.35 AFFO: $0.36 Normalized AFFO: $0.37 EBITDARM Coverage Summary: Skilled Nursing/Transitional Care: 1.94x Senior Housing - Leased: 1.37x Behavioral Health, Specialty Hospitals and Other: 3.68x Same store managed senior housing Cash NOI increased 17.8% on a year-over-year basis. As previously announced, in the third quarter of 2024, Sabra close
Sabra Health Care REIT, Inc. ("Sabra") (NASDAQ:SBRA) announced today that Moody's Ratings ("Moody's") issued a report on October 17, 2024 affirming Sabra's Ba1 ratings and upgrading Sabra's outlook to "Positive" from "Stable". The report credits Sabra's upgraded outlook to improving industry fundamentals for skilled nursing and senior housing, which is driving an improvement in Sabra's key credit metrics, particularly net debt to EBITDA. For additional information, Moody's Ratings report can be found on its website at www.moodys.com. About Sabra Sabra Health Care REIT, Inc., a Maryland corporation, operates as a self-administered, self-managed real estate investment trust (a "REIT") that
Sabra Health Care REIT, Inc. ("Sabra") (NASDAQ:SBRA) today announced that Jessica Flores has been appointed Executive Vice President and Chief Accounting Officer and, in such capacity, has been designated by the Company's Board of Directors as the Company's principal accounting officer. Ms. Flores currently serves as Sabra's Senior Vice President – Finance and Controller, a position she has held since January 2022. Ms. Flores joined Sabra in March 2011 and held various leadership positions overseeing Sabra's accounting during that time. Ms. Flores has over 15 years of experience in accounting, finance and real estate investments, having previously worked for KBS Realty Advisors and Deloit
IRVINE, Calif.--(BUSINESS WIRE)--Sabra Health Care REIT, Inc. (“Sabra”) (Nasdaq: SBRA) today announced the appointment of Katie Cusack to its Board of Directors. Ms. Cusack currently serves as Chief Operating Officer of Cornell Capital LLC, a $4 billion private investment firm with offices in New York and Hong Kong. From 2007 to 2020, Ms. Cusack served in various capacities at Credit Suisse, including Chief Operating Officer for the Investment Banking Division in both Asia Pacific and Europe, Middle East and Africa, and as the Head of Ultra-High Net Worth Coverage. Prior to joining Credit Suisse, Ms. Cusack served as a Managing Director at MTS Health Partners LP, where she provided
IRVINE, Calif.--(BUSINESS WIRE)--Sabra Health Care REIT, Inc. (“Sabra”) (Nasdaq: SBRA) today announced the appointment of Ann Kono to its Board of Directors. Ms. Kono currently serves as the chief executive officer of Leda Advisory Group, a management consulting firm she founded in January 2019 that partners with startup companies to advise on growth and scale. Prior to founding Leda, Ms. Kono spent 11 years at Ares Management Corporation, where she held the position of Chief Information and Risk Officer, and oversaw Operational, Investment and Enterprise Risks. Ms. Kono also serves on the board of directors of Stable Road Acquisition Company, a position she has held since 2019. M
8-K - Sabra Health Care REIT, Inc. (0001492298) (Filer)
10-Q - Sabra Health Care REIT, Inc. (0001492298) (Filer)
424B5 - Sabra Health Care REIT, Inc. (0001492298) (Filer)
4 - Sabra Health Care REIT, Inc. (0001492298) (Issuer)
Truist Securities analyst Michael Lewis maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Buy and raises the price target from $15 to $16.
Scotiabank analyst Nicholas Yulico maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Sector Perform and raises the price target from $14 to $15.
2024 GUIDANCESabra is reiterating 2024 earnings guidance ranges as follows (attributable to common stockholders, per diluted common share):Net Income: $0.53 - $0.57FFO: $1.33 - $1.37Normalized FFO: $1.34 - $1.38AFFO: $1.38 - $1.42Normalized AFFO: $1.39 - $1.43Earnings guidance above assumes no 2024 acquisition or disposition activity.Commenting on the first quarter's results, Rick Matros, CEO and Chair, said, "As has been evident for several quarters, Sabra's portfolio continues to grow stronger, whether looking at coverage, occupancy, or NOI. Trailing-twelve-month SNF coverage saw a healthy 0.06x increase sequentially, to 1.79x, when excluding the impact of Provider Relief Funds. Our SHOP p